Research analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO – Get Free Report) in a report released on Wednesday. The firm set a “strong-buy” rating on the medical research company’s stock.
Global Cord Blood Stock Performance
NYSE CO opened at $1.20 on Wednesday. The stock has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $1.33. Global Cord Blood has a twelve month low of $2.03 and a twelve month high of $5.50. The stock has a market capitalization of $145.86 million, a PE ratio of 1.88 and a beta of 0.16.
Global Cord Blood Company Profile
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Further Reading
Receive News & Ratings for Global Cord Blood Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Global Cord Blood and related companies with MarketBeat.com’s FREE daily email newsletter.
Read More
